

July 28, 2017

The Manager- Listing

BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai - 400001

The Manager- Listing

National Stock Exchange of India Limited

Exchange plaza, 5th Floor, Plot No. C/1, G Block
Bandra –Kurla Complex, Bandra (E),
Mumbai - 400051

Dear Sir(s),

Subject: Termination of distribution arrangements for Meronem in India by AstraZeneca UK Limited - Extension of date of withdrawal

We refer to our announcement dated August 24, 2016 intimating the exchanges about the termination of distribution arrangement by AstraZeneca UK Limited for Meronem in India, pursuant to a global agreement by AstraZeneca PLC to sell the development and commercialization rights to Pfizer Inc., of its late-stage small molecule antibiotics business.

We also refer to our announcement dated December 1, 2016 intimating the exchanges about the validity period of the distribution agreement being extended upto July 31, 2017, due to delay in the divestment of AstraZeneca's global rights to Meronem and our further announcement dated January 19, 2017 intimating the exchanges about the transitional arrangements with Pfizer during the interim period.

We now wish to further update that the Company has received a letter from AstraZeneca UK Limited to further extend the date of withdrawal of Meronem from July 31, 2017 to August 31, 2017, due to the delay in the divestment of AstraZeneca's global right to Meronem.

Kindly take the same on record.

For AstraZeneca Pharma India Limited



Pratap Rudra

Company Secretary & Legal Counsel